APA (7th ed.) Citation
(2026). Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. IJU Case Reports.
Chicago Style (17th ed.) Citation
"Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report." IJU Case Reports 2026.
MLA (9th ed.) Citation
"Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report." IJU Case Reports, 2026.
Warning: These citations may not always be 100% accurate.